Episode 32: The inflammation-microbiome connection and how new therapies can correct both.
Biological therapies like dupilumab target type 2 inflammation, now new research shows they also modify the skin microbiome. In this episode we discuss what type 2 inflammation is, why it matters in eczema, and how these therapies modify the skin microbiome with Dr. Lisa Beck, Co-Director, Center for Allergic Disease Research, University of Rochester Medical Center, NY. (If you like our podcast consider supporting it with a tax deductible donation.) Check out the transcript here.
Research associated with this podcast:
Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis
Rapid Reduction in Staphylococcus aureus in Atopic Dermatitis Subjects Following Dupilumab Treatment
